Medication info

Bacrax Injection 250 mg (Acyclovir)

Prescription medicationIntravenous injection
Ingredient · strength
Acyclovir›250mg / 1 vial
Manufacturer / importer
Aprogen Biologics Co., Ltd.
Appearance
A vial containing white powder
Packaging
10 vials/case (for domestic use, for export)
Approval status
Active

MFDS item code 199700475 · Notified 1997.03.03 · Insurance code 645204451

Summary

Main use
Treatment and prevention of herpes simplex, chickenpox and shingles, and herpes simplex encephalitis
Who receives it
Adults · Children
Adult administration
○ Adults 1. Treatment of herpes simplex virus infections 1) Administer acyclovir 200 mg 5 times daily at 4-hour intervals for 5 days. In cases of severe primary infection, treatment may be extended. 2) In patients with severe immunocompromise (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose may be increased to 400 mg per administration or the route of administration may be changed to intravenous injection. 3) It is preferable to begin treatment as soon as possible after infection; in recurrent cases, treatment should preferably be started at the first sign of prodromal symptoms or lesions. 2. Prevention of herpes simplex infections in patients with normal immune function 1) Administer this drug 200 mg 4 times daily at approximately 6-hour intervals. Alternatively, 400 mg may be administered twice daily at 12-hour intervals. 2) The dose may subsequently be reduced to 200 mg 2~3 times daily, after which it may be further reduced once its efficacy has been confirmed. 3) To assess the natural course of the disease, long-term treatment should be periodically discontinued every 6~12 months for evaluation. 3. Prevention of herpes simplex infections in patients with impaired immune function 1) Administer this drug 200 mg 4 times daily at approximately 6-hour intervals. 2) In patients with severe immunocompromise (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose may be increased to 400 mg per administration or the route of administration may be changed to intravenous injection. 3) Administer during the period of risk of infection. 4. Treatment of herpes zoster infections 1) Administer this drug 800 mg 5 times daily at approximately 4-hour intervals, excluding bedtime, for a total of 7 days. 2) Intravenous administration should be considered for patients with severe immunocompromise or gastrointestinal malabsorption. 3) It is preferable to begin treatment as soon as possible after infection; the earlier treatment is started, the better the effect. ○ Patients with renal impairment Patients with renal impairment are more likely to experience adverse neuropsychiatric reactions; caution should be exercised, including by extending the dosing interval or reducing the dose. 1. Treatment of herpes simplex infections The oral dose is generally not higher than the amount that would accumulate following intravenous injection. However, in patients with severe renal impairment (creatinine clearance less than 10 mL/minute), it is preferable to administer this drug 200 mg every 12 hours. 2. Treatment of varicella-zoster virus infections In patients with severe renal impairment (creatinine clearance less than 10 mL/minute), it is preferable to reduce the dose of this drug to 800 mg per administration 3~4 times daily, at approximately 6~8-hour intervals. (Injection) Administer the injection slowly by intravenous infusion over at least 1 hour each time. A treatment period of 5 days is appropriate, but it may be adjusted according to the patient's symptoms and healing status. Herpes simplex encephalitis is usually treated for 10 days. 1. Adults 1) Herpes simplex infections: In patients with normal or impaired immune function, administer acyclovir 5 mg/kg body weight every 8 hours. 2) Recurrent varicella-zoster virus infections: In patients with normal immune function, administer this drug 5 mg/kg body weight every 8 hours. 3) Primary and recurrent varicella-zoster virus infections: In patients with impaired immune function, administer this drug 10 mg/kg body weight every 8 hours. 4) Herpes simplex encephalitis: In patients with normal or impaired immune function, administer this drug 10 mg/kg body weight every 8 hours. 5) Prevention of herpes simplex virus infections in patients with impaired immune function: Consider this treatment when oral administration is not possible, and determine the treatment duration according to the period of risk of infection. 6) If acyclovir is administered intravenously to obese patients based on actual body weight, plasma concentrations may increase. Therefore, dose reduction should be considered in obese patients, particularly those with renal impairment or elderly patients. 2. Patients with renal impairment are more likely to experience adverse neuropsychiatric reactions; use caution during administration. The dosage is as follows. Creatinine clearance (mL/min) 25~50 Administer the recommended dose for the indication above every 12 hours 10~25 Administer the recommended dose for the indication above every 24 hours 0 (anuria)~10 For patients receiving peritoneal dialysis, administer half the recommended dose (2.5 or 5 mg/kg body weight) every 24 hours. For patients receiving hemodialysis, administer half the recommended dose (2.5 or 5 mg/kg body weight) every 24 hours and after dialysis. 4. Preparation of solution Dissolve 1 vial (containing acyclovir 250 mg) by adding 10 mL of Water for Injection or 0.9%w/v Normal Saline Injection for intravenous use. Then administer intravenously using an infusion pump that allows the infusion volume to be controlled, or dilute and administer by intravenous infusion. 5. Method of administration 1) For intravenous administration using an infusion pump, administer the acyclovir 25 mg/mL solution as is over at least 1 hour. 2) For diluted intravenous infusion, the acyclovir concentration should be 0.5%w/v or less. Dilute a vial containing 250 mg in at least 50 mL of solution and administer over at least 1 hour. 3) For dilution in this case, the following infusion solutions may be used; the solutions are stable for 12 hours at room temperature (15~25℃). (1) 0.45%w/v or 0.9%w/v Normal Saline Injection for infusion (2) A mixture of 0.18%w/v Normal Saline Injection and 4%w/v Glucose Injection for infusion (3) A mixture of 0.45%w/v Normal Saline Injection and 2.5%w/v Glucose Injection for infusion (4) Compound Sodium Lactate Solution for infusion (Hartmann's solution) 4) After adding this drug to the infusion solution, shake the mixture to ensure it is thoroughly mixed. 5) If cloudiness or crystals are visible in the solution before or during infusion, discard the mixture. Do not refrigerate the solution.
Child administration
○ Children 1. Treatment of herpes simplex infections and prevention of herpes simplex infections in patients with impaired immune function Age 2 years and older: Same as for adults. Under 2 years: Administer 1/2 the adult dose. Treatment of chickenpox in children aged 2 years and older: Administer 20 mg per kg of body weight per dose (maximum 800 mg per dose) 4 times daily for 5 days. 3. Children The dose for children (3 months~12 years) is calculated according to body surface area and administered according to the adult regimen. 1) Herpes simplex (excluding herpes simplex encephalitis) or varicella-zoster virus infection: Administer 250 mg per ㎡ of body surface area every 8 hours. 2) Immunocompromised children with varicella-zoster infection or herpes simplex encephalitis: If renal function is normal, administer 500 mg per ㎡ of body surface area every 8 hours. Adjust the dose appropriately according to the degree of impairment in pediatric patients with renal impairment.

Ingredients

Manufacturer
Aprogen Biologics Co., Ltd.

Efficacy & effects

Treatment and prevention of herpes simplex, chickenpox and shingles, and herpes simplex encephalitis

  • Primary genital herpes
  • recurrent genital herpes
  • herpes simplex virus infections of the skin and mucous membranes
  • varicella-zoster virus infections
  • acute pain
  • chickenpox
  • severe primary genital herpes
  • recurrent varicella-zoster virus infections
  • herpes simplex encephalitis
  • herpes simplex virus infections
  • primary varicella-zoster virus infections
  • recurrent varicella-zoster virus infections
View approved original text

This medication is used for the treatment and prevention of herpes simplex virus infections of the skin and mucous membranes, including primary and recurrent genital herpes. It also treats varicella-zoster virus infections and is particularly effective in alleviating pain that occurs during the acute phase. In children over 2 years of age, it is also used for the treatment of chickenpox. The injectable form is used for severe genital herpes, recurrent varicella-zoster virus infections, and herpes simplex encephalitis in immunocompetent patients. It is also effective for the treatment and prevention of herpes simplex virus infections, primary and recurrent varicella-zoster virus infections, and herpes simplex encephalitis in immunocompromised patients. This drug is used to improve and treat various symptoms caused by viral infections.

How it is given

Adult administration

○ Adults 1. Treatment of herpes simplex virus infections 1) Administer acyclovir 200 mg 5 times daily at 4-hour intervals for 5 days. In cases of severe primary infection, treatment may be extended. 2) In patients with severe immunocompromise (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose may be increased to 400 mg per administration or the route of administration may be changed to intravenous injection. 3) It is preferable to begin treatment as soon as possible after infection; in recurrent cases, treatment should preferably be started at the first sign of prodromal symptoms or lesions. 2. Prevention of herpes simplex infections in patients with normal immune function 1) Administer this drug 200 mg 4 times daily at approximately 6-hour intervals. Alternatively, 400 mg may be administered twice daily at 12-hour intervals. 2) The dose may subsequently be reduced to 200 mg 2~3 times daily, after which it may be further reduced once its efficacy has been confirmed. 3) To assess the natural course of the disease, long-term treatment should be periodically discontinued every 6~12 months for evaluation. 3. Prevention of herpes simplex infections in patients with impaired immune function 1) Administer this drug 200 mg 4 times daily at approximately 6-hour intervals. 2) In patients with severe immunocompromise (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose may be increased to 400 mg per administration or the route of administration may be changed to intravenous injection. 3) Administer during the period of risk of infection. 4. Treatment of herpes zoster infections 1) Administer this drug 800 mg 5 times daily at approximately 4-hour intervals, excluding bedtime, for a total of 7 days. 2) Intravenous administration should be considered for patients with severe immunocompromise or gastrointestinal malabsorption. 3) It is preferable to begin treatment as soon as possible after infection; the earlier treatment is started, the better the effect. ○ Patients with renal impairment Patients with renal impairment are more likely to experience adverse neuropsychiatric reactions; caution should be exercised, including by extending the dosing interval or reducing the dose. 1. Treatment of herpes simplex infections The oral dose is generally not higher than the amount that would accumulate following intravenous injection. However, in patients with severe renal impairment (creatinine clearance less than 10 mL/minute), it is preferable to administer this drug 200 mg every 12 hours. 2. Treatment of varicella-zoster virus infections In patients with severe renal impairment (creatinine clearance less than 10 mL/minute), it is preferable to reduce the dose of this drug to 800 mg per administration 3~4 times daily, at approximately 6~8-hour intervals. (Injection) Administer the injection slowly by intravenous infusion over at least 1 hour each time. A treatment period of 5 days is appropriate, but it may be adjusted according to the patient's symptoms and healing status. Herpes simplex encephalitis is usually treated for 10 days. 1. Adults 1) Herpes simplex infections: In patients with normal or impaired immune function, administer acyclovir 5 mg/kg body weight every 8 hours. 2) Recurrent varicella-zoster virus infections: In patients with normal immune function, administer this drug 5 mg/kg body weight every 8 hours. 3) Primary and recurrent varicella-zoster virus infections: In patients with impaired immune function, administer this drug 10 mg/kg body weight every 8 hours. 4) Herpes simplex encephalitis: In patients with normal or impaired immune function, administer this drug 10 mg/kg body weight every 8 hours. 5) Prevention of herpes simplex virus infections in patients with impaired immune function: Consider this treatment when oral administration is not possible, and determine the treatment duration according to the period of risk of infection. 6) If acyclovir is administered intravenously to obese patients based on actual body weight, plasma concentrations may increase. Therefore, dose reduction should be considered in obese patients, particularly those with renal impairment or elderly patients. 2. Patients with renal impairment are more likely to experience adverse neuropsychiatric reactions; use caution during administration. The dosage is as follows. Creatinine clearance (mL/min) 25~50 Administer the recommended dose for the indication above every 12 hours 10~25 Administer the recommended dose for the indication above every 24 hours 0 (anuria)~10 For patients receiving peritoneal dialysis, administer half the recommended dose (2.5 or 5 mg/kg body weight) every 24 hours. For patients receiving hemodialysis, administer half the recommended dose (2.5 or 5 mg/kg body weight) every 24 hours and after dialysis. 4. Preparation of solution Dissolve 1 vial (containing acyclovir 250 mg) by adding 10 mL of Water for Injection or 0.9%w/v Normal Saline Injection for intravenous use. Then administer intravenously using an infusion pump that allows the infusion volume to be controlled, or dilute and administer by intravenous infusion. 5. Method of administration 1) For intravenous administration using an infusion pump, administer the acyclovir 25 mg/mL solution as is over at least 1 hour. 2) For diluted intravenous infusion, the acyclovir concentration should be 0.5%w/v or less. Dilute a vial containing 250 mg in at least 50 mL of solution and administer over at least 1 hour. 3) For dilution in this case, the following infusion solutions may be used; the solutions are stable for 12 hours at room temperature (15~25℃). (1) 0.45%w/v or 0.9%w/v Normal Saline Injection for infusion (2) A mixture of 0.18%w/v Normal Saline Injection and 4%w/v Glucose Injection for infusion (3) A mixture of 0.45%w/v Normal Saline Injection and 2.5%w/v Glucose Injection for infusion (4) Compound Sodium Lactate Solution for infusion (Hartmann's solution) 4) After adding this drug to the infusion solution, shake the mixture to ensure it is thoroughly mixed. 5) If cloudiness or crystals are visible in the solution before or during infusion, discard the mixture. Do not refrigerate the solution.

Child administration

○ Children 1. Treatment of herpes simplex infections and prevention of herpes simplex infections in patients with impaired immune function Age 2 years and older: Same as for adults. Under 2 years: Administer 1/2 the adult dose. Treatment of chickenpox in children aged 2 years and older: Administer 20 mg per kg of body weight per dose (maximum 800 mg per dose) 4 times daily for 5 days. 3. Children The dose for children (3 months~12 years) is calculated according to body surface area and administered according to the adult regimen. 1) Herpes simplex (excluding herpes simplex encephalitis) or varicella-zoster virus infection: Administer 250 mg per ㎡ of body surface area every 8 hours. 2) Immunocompromised children with varicella-zoster infection or herpes simplex encephalitis: If renal function is normal, administer 500 mg per ㎡ of body surface area every 8 hours. Adjust the dose appropriately according to the degree of impairment in pediatric patients with renal impairment.

Precautions

This medication should not be used in patients who are allergic to this drug or its ingredients or who have hypersensitivity reactions. For patients with poor kidney function, there may be neuropsychiatric adverse reactions when using this medication, so caution is advised. Patients with impaired liver function should be given this medication carefully, as there is a risk of further liver function deterioration. In infants and children, it should only be used at the minimum dose necessary, and particular caution is required in newborns or premature infants, as safety has not been established. Elderly patients are more likely to have decreased kidney function, which can lead to increased blood levels of this drug; therefore, dosage and administration intervals should be adjusted and used cautiously. During the use of this medication, serious allergic reactions such as anaphylactic shock may rarely occur. If symptoms such as low blood pressure, difficulty breathing, or chest tightness appear, use should be immediately discontinued, and medical attention should be sought. Additionally, if hypersensitivity reactions such as skin rashes, fever, blisters, or urticaria occur, the administration of this medication should be stopped, and appropriate treatment should be obtained. Skin-related side effects such as hair loss, erythema multiforme, and severe skin diseases (Stevens-Johnson syndrome, toxic epidermal necrolysis) may occur, so caution is needed. Neuropsychiatric symptoms may occur, including altered consciousness, disorientation, decreased concentration, aggressive behavior, hallucinations, seizures, drowsiness, insomnia, and anxiety, and these symptoms may be more frequent in the elderly or in patients with impaired kidney function. Kidney-related side effects can include renal failure, hematuria, proteinuria, and pyuria, so it is important to periodically monitor kidney function. Liver dysfunction or symptoms of hepatitis or jaundice may occur, so regular liver function tests should be performed. Gastrointestinal issues such as gastritis, nausea, vomiting, abdominal pain, and diarrhea may arise; if symptoms worsen, it is advisable to consult a healthcare professional. Adequate fluid intake is necessary while using this medication, especially during high doses, to prevent dehydration and reduce the risk of kidney toxicity. Women who are pregnant or may become pregnant should only use this medication if the benefits outweigh the risks to the fetus, and breastfeeding should be discontinued if using this medication. This medication may interact with other drugs, so it is essential to inform your healthcare provider or pharmacist about any other medications you are currently taking. In case of overdose, symptoms such as mental confusion, seizures, or coma may occur, which can cause kidney damage, so immediate medical assistance should be sought. This medication is most effective when administered as soon as possible, particularly within 3 to 5 days after symptoms begin. When administered intravenously, it should be given slowly via a drip infusion, as rapid administration can damage the kidneys. While using this medication, it is important to carefully monitor for adverse reactions and consult healthcare providers immediately if any abnormal symptoms arise.

Side effects

  • Anaphylactic shock
  • anaphylactic reaction
  • hypotension
  • dyspnea
  • chest tightness
  • photosensitivity reaction
  • fixed drug eruption
  • rash
  • fever
  • vesicles
Show 126 more
  • urticaria-like erythema
  • urticaria
  • alopecia
  • erythema multiforme
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • altered consciousness
  • disorientation
  • concentration impairment
  • aggressive behavior
  • depersonalization
  • anxiety
  • akinesia
  • lethargy
  • confusion
  • delirium
  • stuttering
  • encephalopathy
  • hallucinations
  • psychosis
  • seizures
  • drowsiness
  • tremors
  • excitement
  • memory loss
  • insomnia
  • anxiety
  • soliloquy
  • abnormal sensations
  • ataxia
  • inability to walk
  • involuntary movements
  • nystagmus
  • renal failure
  • crystalluria
  • increased BUN
  • elevated serum creatinine
  • hematuria
  • proteinuria
  • red blood cell casts in urine
  • pyuria
  • leukocytoclastic vasculitis
  • lymphadenopathy
  • bleeding
  • purpura
  • anemia
  • leukopenia
  • leukocytosis
  • eosinophilia
  • lymphocytosis
  • thrombocytosis
  • granulocytopenia
  • thrombocytopenia
  • basophilia
  • hepatitis
  • liver impairment
  • jaundice
  • abnormal liver function tests
  • hepatomegaly
  • gastritis
  • thirst
  • constipation
  • acute pancreatitis
  • diarrhea
  • loose stools
  • upper abdominal pain
  • gastric pain
  • abdominal pain
  • nausea
  • vomiting
  • dyspepsia
  • loss of appetite
  • glossitis
  • fever
  • peripheral edema
  • syncope
  • paleness
  • muscle weakness
  • malaise
  • generalized fatigue
  • headache
  • arthralgia
  • myalgia
  • arrhythmia
  • chest pain
  • hypertension
  • hypotension
  • tachycardia
  • palpitations
  • urinary obstruction
  • dysuria
  • glycosuria
  • pneumonia
  • pharyngitis
  • pleurisy
  • pain
  • hearing loss
  • conjunctivitis
  • visual disturbances
  • taste disorders
  • sweating
  • hyponatremia
  • hypoalbuminemia
  • increased total cholesterol levels
  • elevated triglycerides
  • increased serum potassium levels
  • decreased serum albumin levels
  • nonsensical speech
  • speech disorder
  • paresthesia of the lower limbs
  • numbness of the tongue and extremities
  • bipolar disorder
  • emotional instability
  • concentration impairment
  • forgetfulness
  • ataxia
  • gait abnormalities
  • involuntary movements
  • edema
  • coldness
  • sensation of chest tightness
  • vascular pain
  • rapid vascular weakening
  • ulcers
  • agranulocytosis
  • disseminated intravascular coagulation

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent air or moisture from entering, ideally at a cool temperature below 25 degrees Celsius. Proper storage will maintain the efficacy of the medication and prevent degradation.

Appearance and packaging

Appearance

A vial containing white powder

Package unit

10 vials/case (for domestic use, for export)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.